REV-ERBα MITIGATES HEART FAILURE BY EXERTING TRANSCRIPTIONAL REPRESSION: A LITERATURE REVIEW

Received 2023-05-22; Accepted 2024-03-20; Published 2024-09-11

Abstract

Heart failure (HF) is a major cause of mortality, affecting millions of people in the United States. Current treatments focus on minimizing stress and improving hemodynamics, but there is still a need for an effective strategy that can selectively inhibit the abnormal gene program associated with HF. Rev-erb, a member of the nuclear receptor superfamily, has been identified as a potential therapeutic target for HF due to its role in regulating circadian rhythm, glucose and lipid metabolism, and inflammation. Synthetic Rev-erb agonists have shown promise in preclinical studies, improving metabolic and inflammatory pathways while also enhancing mitochondrial function. Long-term therapy with these agonists has also been shown to reduce atherosclerotic plaque. While more research is needed to fully understand Rev-erb’s functions in HF development, it represents a potentially exciting new avenue for treatment. This literature review explores the potential use of Rev-erb agonists as a therapeutic target for HF patients.